Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The relationship of the effective dose and safety of cinacalcet hydrochloride and etelcalcetide hydrochloride in the Japanese patients with secondary hyperparathyroidism receiving hemodialysis, when switching cinacalcet hydrochloride to etelcalcetide hydrochloride.

Next Previous
Trial Profile

The relationship of the effective dose and safety of cinacalcet hydrochloride and etelcalcetide hydrochloride in the Japanese patients with secondary hyperparathyroidism receiving hemodialysis, when switching cinacalcet hydrochloride to etelcalcetide hydrochloride.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etelcalcetide (Primary) ; Cinacalcet
  • Indications Secondary hyperparathyroidism
  • Focus Therapeutic Use

Most Recent Events

  • 13 Mar 2019 Status changed from active, no longer recruiting to completed.
  • 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.
  • 21 Jun 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top